Small Cap Feast

21st January 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
No joiners today.
Off The Menu:
No Leavers Today.

What’s Cooking In The IPO Kitchen?

Hercules Site Services a technology enabled labour supply company for the UK infrastructure sector, intends to float on AIM. Hercules is seeking to raise approximately £5.5m to rapidly deliver on the significant demand it is experiencing for its diverse range of services across the UK infrastructure sector, including to scale up its operations to supply labour to the northern section of the HS2 rail project from London to Birmingham. In addition, up to £4.5m will be raised for the existing shareholder from the sale of part of its interest in the Company. Hercules has a sustained track record of revenue growth from £9.7m in FY 2015 to £30.7m in FY 2019 and has experienced a strong rebound following Covid-19 growing to £14.0m in H1 FY 2021. Expected early Q1 2022.

Spinnaker Acquisitions plc, intends to join the Main Market (Standard). The Company have conditionally agreed to acquire the entire issued share capital of HomeServe Labs Ltd, a wholly owned subsidiary of FTSE250 quoted public company HomeServe Plc, by way of a reverse takeover conditional, inter alia on relisting and successful completion of fundraising activities to be undertaken by way of a placing and direct subscriptions by new and existing investor. If the Proposed Transaction proceeds to completion, it is proposed to change the name of the Company to Ondo InsurTech Plc and the name of Labs, which will become a subsidiary of the Company, to LeakBot Ltd. Should the Proposed Transaction not proceed, then the Company would need to apply for the suspension of its listing of ordinary shares to be lifted and for trading to be restored. £5m capital to be raised. Due early 2022.

Unbound Group PLC, (currently called Electra Private Equity PLC) to join AIM. Unbound Group, will be the parent company for a range of brands focused on the 55 plus demographic. Initially focused on Hotter Shoes, Unbound’s curated, multi-brand retail platform will offer additional products and services that will enhance the enjoyment and wellbeing of its targeted customer community. This online platform will be based on the foundations of Hotter Shoes as a trusted brand, cloud-based digital infrastructure, and strong customer personalisation through data insight. No capital being raised on Admission. Anticipated Mkt Cap c.£30m. Due 31st Jan.

Clean Power Hydrogen, the UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser is seeking to join AIM. The Group designs and manufactures hydrogen production units and is focused on the commercial production of green hydrogen in a simple, safe, and sustainable manner. The Group intends to raise approximately £50m. Timing TBC.

SuperSeed Capital Limited, to join the AQSE Growth Market. The Company will invest in technology-led innovation primarily through unquoted funds managed by SuperSeed Ventures, the Company’s Investment Manager, with the objective of maximising the investors’ long term total returns – principally through capital appreciation. Mkt Cap and Capital to be raised TBC.

Carbon Air, a nano-technology company which leverages the adsorption properties of activated carbon and other advanced materials to improve suspension systems, enhance acoustics or reduce noise, to join AIM. The Company’s proprietary technology has allowed it to develop a unique portfolio of solutions for a variety of sizeable end markets, including vehicle suspension systems, acoustic insulation for domestic appliances and micro-speakers for smartphones. Mkt Cap and Capital to be raised TBC. Due Late Jan.

i(x) Net Zero, the investing company which focusses on Energy Transition and Sustainability in the Built Environment, announces its intention to join AIM and raise money to provide development and expansion capital to certain of its investee companies, for future investments in companies that fall primarily within its areas of interest in Energy Transition and Sustainability in the Built Environment and to provide working capital for the Group. Capital to be raised £20m. Expected admission late Jan.

Spiritus Mundi due to join the Main Market (Standard), a special purpose acquisition vehicle which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector. The Company has already raised approximately £1.2m in a pre-IPO fundraising round. Due late Jan 2022.

Recycling Tech Group to join AIM, a UK-based engineering, research and manufacturing company that has developed a modular and mass producible machine, the RT7000, which processes hard to recycle plastic waste into a synthetic oil that can be sold back to the petrochemicals industry as a chemical feedstock to make new plastics. Targeting a £40m raise. Due early Q1 2022.

Nu-Oil and Gas to acquire Guardian Maritime Ltd and Guardian Barriers IP Ltd and become Guardian Global Security plc and join the Main Market (Standard). Guardian is a technology group that supplies products to prevent unauthorised entry into areas that are deemed to have value, with maritime security being the main focus initially. Due late Jan 2022.

Superdielectrics to join AIM, a Company which is focused on developing technology to build supercapacitors with high energy density, low cost, and environmentally benign electrical energy storage devices that will help create a clean and sustainable global energy and transportation system. Admission is expected to take place in Late Jan 2022. Mkt Cap and Capital to be raised TBC.

Breakfast Buffet

ADM Energy* 0.93p £1.9m (ADME.L)

The natural resources investing company, has raised a total of £561k through a subscription from Optima Resources Holding Limited, a family office owned natural resources investment company registered and based in the United Arab Emirates. The subscription price is 1.11p. In connection with the Subscription, the Company will, on Admission, issue 15.3m warrants to Optima Resources to subscribe for ordinary shares at an exercise price of 4.5 pence per share with an exercise period of two years from the date of Admission. The funds will be used for general working capital including business development and due diligence on target assets, appraisals and technical evaluation. The Company continues to evaluate investment opportunities, which the board considers may have the potential to add and bring in significant value to ADM.

Angle 127p £301m (AGL.L)

The liquid biopsy company, announced that the Edith Cowan University, Perth, Australia, has published results from a study in ovarian cancer patients using the Parsortix® system. The primary aim of this study was to demonstrate the ability to evaluate the expression of both epithelial and mesenchymal markers, as well as PD-L1 status, of circulating tumour cells (CTCs) isolated using the Parsortix system, which may help to predict whether patients will respond to immunotherapy drugs. The Parsortix system was selected by researchers for the study due to its ability for unbiased CTC enrichment, enabling the isolation of both epithelial and mesenchymal cancer cells and those in transition (EMTing-CTCs). This is clinically relevant because, although the transition to a mesenchymal phenotype is associated with increased metastatic potential and worse prognosis, many CTC isolation methods, including the leading antibody-based system, only capture epithelial cells and miss mesenchymal and EMTing cells. This study highlights the potential for this multi-marker staining procedure to be useful in PD-L1 status investigation, evaluating its utility as a biomarker to select patients for inclusion in clinical trials that are likely to respond better to immunotherapy treatments. Currently the proportion of patients that respond to PD-L1 or PD-1 inhibitors is low, at around 13% to 50%, indicating a clear need for improved patient selection as non-responders do not benefit from treatment but risk developing hyper-progressive disease and drug toxicity with immune-related adverse events.

British Honey Company 115p £18.94m (AQSE:BHC)

The producer of premium British Honey and craft spirits products, announced the appointment to the board of Jonathan Morley-Kirk as Chief Financial Officer with effect from 24 January 2022. Jonathan is a highly experienced CFO with a breadth of experience across quoted and growth orientated private companies in both executive and non-executive roles. Jonathan qualified as a Fellow of the Institute of Chartered Accountants in 1996 and is a Fellow of the Chartered Institute of Securities and Investment. BHC’s current Finance Director, Nicholas Agbo will move to a non-board role as Commercial Director and will lead the Company’s strategic development plans as it seeks to grow the business rapidly in the coming years.

Character Group 615p £131.5m (CCT.L)

AGM Statement from the Group engaged in the design, development and international distribution of toys, games and giftware. “The Group maintained a steady performance in the lead up to and through the Christmas 2021 period, notwithstanding global logistical challenges which continue to impact the export of product from the Far East to UK and our global markets. Whilst the consequent escalation in freight rates from the Far East has significantly increased costs, the Group has endeavoured, where possible, to raise its prices in the UK and Scandinavia to mitigate the impact on margins. Turnover increased by c. 23% in the four-month period ended 31 December 2021 compared to the previous year (in part benefiting from delayed shipments in August 2021). The bulk of this growth was attributable to sales to the USA and Scandinavia, whilst turnover in the UK and the rest of the world remained largely flat. Our sales levels are a reflection of the strong portfolio of brands and products that we have at this time. In the UK, retailers have reported good sell through of our products and this bodes well for the rest of the financial year. Our teams are excited to be presenting to our customers at the London Toy Fair at Olympia next week (25 – 27 January) and showcasing the 2022 range and introducing new products, brands and refreshed items. Assuming no further worsening of the trading conditions, including adverse COVID developments impacting normal commercial activity, the Board believes that the Group will achieve current market expectations for the year ending 31 August 2022.”

Destiny Pharma 103.5p £62m (DEST.L)

The clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today notes the publication of a major Lancet study highlighting that over 1m deaths occurred in 2019 due to bacterial Antimicrobial Resistance (AMR) and that AMR is one of the leading causes of death across the world. The report also notes the importance of infection prevention in mitigating AMR and names Staphylococcus aureus as one of the six leading lethal pathogens. Neil Clark, Chief Executive Officer of Destiny Pharma, said: “This report validates the very real clinical need and potential global commercial opportunity for our XF platform as it delivers clinical candidates that prevent infections whilst addressing the threat of AMR. The excellent results from our Phase 2b study demonstrate the potential of our XF-73 nasal gel to prevent post-surgical infections caused by S. aureus, such as MRSA, and we are focused on finalising the Phase 3 clinical trial plans. Additionally, we are testing XF-73 in two dermal infection preclinical programmes.”

Everyman Media Group 145p £132.2m (EMAN.L)

Everyman is the fourth largest cinema business in the UK by number of venues, and is a premium, high growth leisure brand. Pre-audit trading update for the 52-week period ended 30 December 2021. Group revenue of £48.7m (2020: £24.2m), an increase of 101% year-on-year with 33 weeks trading, driven by strong admissions since re-opening. Compares to 2020 which saw 10 weeks of normal trading, 17 weeks of disrupted trading and 25 weeks of full closure due to COVID-19 restrictions. 2021 revenue was at 75% of the 2019 FY total (£65m) despite having 19 weeks closed, particularly pleasing given 2019 was a record year for the Group. Due to a better than expected performance in December, EBITDA is expected to be ahead of current market forecast at approximately £8.3m (2020: £1.1m loss). Everyman now operates 36 venues, with one new venue at Borough Yards opened in the period, in December 2021. The total number of screens now operated by the Group is 119 (2020: 117). Since re-opening on 17 May 2021 the Group has been EBITDA positive and operating cash generative each month. The outlook for the business is positive, reinforced by healthy admissions since re-opening and the Group’s roll-out programme set to recommence in earnest with a committed pipeline of five new venues for the current financial year: Edinburgh, Plymouth, Durham, Marlow and Egham.

One Heritage Group* 51.5p £16.7m (OHG.L)

The UK-based residential developer focused on the North of England, has signed a 12 month extension to its two loans from One Heritage SPC. The original loans of £1.1m and £1.0m were issued on 22 July 2020 and 11 August 2020, respectively. They both had a 18 month term and 12.0% interest rate. The extensions have been made at the same interest rate and allow early repayment.

OnTheMarket 121p £90m (OTMP.L)

The majority agent-owned company announced an update on trading. In the announcement of its interim results on 12 October 2021, OnTheMarket stated that the Group expected to achieve approximately breakeven adjusted operating profit for the six months ended 31 January 2022. The Group’s operational performance has continued to be strong through H2 21/22 and revenues for the full year ended 31 January 2022 are now expected to be slightly ahead of market consensus. The Company’s focus on disciplined operational and cost management has continued. When combined with a higher level of development investment in the new website and brand launch that will be capitalised rather than expensed as incurred in the income statement, the Group now expects adjusted operating profit1 to be positive in H2 21/22 and to be at least £2.5m for the full year FY 21/22.

Totally 33.5p £61.1m (TLY.L)

The provider of healthcare services across the UK and Ireland, announced that its Urgent Care division has been awarded three new contracts and multiple contract extensions to deliver services across North East England, Staffordshire, Stoke-on-Trent and South East London, together worth a value of more than £54m. Vocare Limited, part of Totally’s Urgent Care Division, has been awarded a new contract with Staffordshire and Stoke-on-Trent CCGs for the provision of GP Out of Hours services (GP OOH). Vocare already provides GP OOH services in Staffordshire and Stoke-on-Trent as part of a contract for Integrated Urgent Care. This new contract, which Vocare secured through a competitive tender process, supports the delivery of care for an increased population of c. 1.2m people. The contract’s total value is £45m over five years, with an option to extend for a further two years. The Company expects to mobilise the service by April 2022. Totally’s Urgent Care Division, which comprises Vocare and Greenbrook Healthcare Limited, has also been awarded two new contracts for the delivery of NHS 111 online clinical services in North East England and South East London Clinical Assessment Services (CAS). The contracts, which will run for a duration of 3 months, complement the NHS 111 telephony services that the division currently delivers. Vocare will deliver the services in North East England and Greenbrook will deliver the services in South East London. Collectively, the two contracts are worth a total of £0.6m. Greenbrook has also been awarded multiple contract extensions for the delivery of Urgent Treatment Centres (UTC) in South East London. The contract extensions are valued at a total of £8.6m and run for periods of between 6 and 12 months.

Westminster Group 3.4p £11.23m (WSG.L)

The supplier of managed services and technology-based security solutions worldwide, announced that the Standstill Period referred to in its $1.7m airport security contract award announcement on 17 December 2021 has now ended and the formal notice of contract award to Westminster has been issued. Accordingly works are expected to begin in February and the project to be completed and recognised during 2022.

21 January 2022
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram